ArticleBMC infectious diseases2025
Survival analysis of risk factors for mortality in pulmonary tuberculosis patients in southeast Iran (2013-2023).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary cavitation as a dominant prognostic indicator in tuberculosis complicated by chronic pulmonary aspergillosis: a retrospective cohort study.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a major global health challenge, particularly in low- and middle-income countries. In Iran, Sistan-and-Baluchistan Province bears a disproportionately high burden of pulmonary tuberculosis due to its geographic, socioeconomic, and healthcare access-related vulnerabilities. Despite national control programs, evidence on survival outcomes and mortality predictors in this region remains limited.
objectiveThis study aimed to determine the survival time and identify key risk factors associated with mortality among smear-positive pulmonary tuberculosis (SPPTB) patients in Sistan-and-Baluchistan Province, southeast Iran.
methodsIn this retrospective cohort study, data from 7,234 SPPTB patients were collected from 2013 to 2023. Information was analyzed using Kaplan-Meier survival estimates, log-rank tests, and multivariable Cox proportional hazards models. Survival time was calculated from the date of the SPPTB diagnosis to the date of death or censoring due to treatment completion, cure, failure, or loss to follow-up. Statistical analyses were conducted using SPSS version 22, with significance set at p < 0.05.
resultsAmong the study population, 526 patients (7.3%) died during treatment. The median survival time was 20.5 months (95% CI: 12.15-28.54). The findings revealed that advanced age, prisoner status, low BMI, Iranian nationality, rural residency, and HIV co-infection were significant predictors of mortality.
conclusionThe study highlights several key risk factors associated with SPPTB-related mortality in a high-burden region of Iran. These findings emphasize the need for targeted interventions, particularly for elderly, malnourished, HIV-positive, and incarcerated individuals, as well as the integration of nutritional and HIV care into SPPTB control programs. Early detection, improved follow-up, and structural support in underserved settings are essential to reduce mortality and align with WHO End TB Strategy targets. CLINICAL TRIAL NUMBER: Not Applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.